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the elderly in 1996. This represents 8.7% of all clinic vis-
its by the elderly for an annual visit rate of 51.97 (visits
for every 100 persons of 65 years old or older). Ninety-
one percent of these visits were to physician offices and
remaining visits were to outpatient clinics. There were
some variations in psychotropic prescribing patterns be-
tween these two settings. Overall, psychotropic medica-
tion visit rates were greater in females, blacks, patients
between 80 and 84 years of age, and patients from the
West. The most frequently prescribed psychotropic medi-
cations in ambulatory clinics in the order of prevalence
were antidepressants, antianxiety agents, and sedatives.
Most of the visits (81.67%) involved one psychotropic
medication and 3.14% of the visits involved two or more
agents in the same class.
CONCLUSION: The study revealed that psychotropic
prescribing practices in ambulatory clinics vary with eld-
erly demographics and clinical settings. Because of the in-
creased risk related to the use of psychotropics and the
prescribing patterns of these agents, future efforts may be
focused on populations receiving relatively more psycho-
tropic agents to improve healthcare outcomes.
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Burden-of-illness assessments require incidence and prev-
alence assumptions. For psychotic disorders, there are
few large-scale incidence and prevalence assessments pro-
viding rates for age, gender, or socioeconomic subpopu-
lations. Because outpatient treatment of psychotic condi-
tions is increasing, overall incidence and prevalence may
be estimated from outpatient pharmaceutical records.
OBJECTIVE: This study estimates incidence and prevalence
of antipsychotic utilization among age, gender, and payer
combinations using outpatient pharmaceutical records.
METHODS: Antipsychotic prescriptions dispensed be-
tween July 1995 and June 1997 to 4,628,528 eligible
subjects were extracted from a large US database. Calcu-
lated ratios compared utilizers (eligible subjects with a
prescription between July 1996 and June 1997) and initi-
ators (utilizers without a prescription between July 1995
and June 1996) to eligible subjects for various combina-
tions of age, gender, and payer types—Medicaid, non-
Medicaid, indemnity, or “self-insured.” Chi-square tests
were used to assess differences between those receiving
and not receiving antipsychotic agents.
RESULTS: The utilizer ratio was 5.0 per 1000, although
significantly (p  0.002) lower (by 1.1 per 1000) for
males. The initiator ratio was 1.6 per 1000, again signifi-
cantly (p  0.001) lower (by 0.1 per 1000) for males.
Differences were not consistent—higher for younger
males and lower for older males than for similarly aged
females. Ratios were significantly (p 	 0.001) higher (by
10 times) for Medicaid recipients.
CONCLUSION: Outpatient ratios were within overall
prevalence and incidence rates for schizophrenia or other
psychotic conditions. Integrating these ratios into a bur-
den-of-illness analysis should consider the proportions of
non-psychotic disorders, patients treated for psychotic
conditions without medication, and patients treated solely
on an inpatient basis.
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Heroin is an extremely devastating drug. Injection of her-
oin is a major risk factor for infectious diseases such as
HIV/AIDS and hepatitis. Heroin addiction often strikes
persons in the prime of their working years, robbing soci-
ety of productive citizens. Furthermore, a significant pro-
portion of heroin users engages in criminal activities to
support their habit.
OBJECTIVE: This study documents the tremendous
costs of heroin addiction, both to the addict and society
at large.
METHODS: Using a cost-of-illness approach, we identify
costs in three major areas: 1) medical care, 2) productivity,
and 3) crime. No single data set currently available is able
to fully capture costs in each of these areas. Thus, a variety
of data sets and previous studies have been synthesized.
RESULTS: We estimate that in 1996 the economic costs
of heroin addiction in the United States totaled $22.1 bil-
lion. Approximately 23% of these costs are due to the
medical complications of heroin addiction, primarily
treatment for HIV/AIDS and psychiatric comorbidities.
Another 24% are related to criminal activities, including
the cost of incarceration, policing, legal adjudication, and
the cost to crime victims. Another 41% are associated
with lost productivity. For example, heroin addicts are
less than half as likely to have a full-time job as com-
pared with the national average. Treatment of heroin ad-
diction and social welfare services each account for 5%
of the costs.
CONCLUSIONS: The significant economic effects of
heroin addiction have important public policy implica-
tions, especially given that heroin use appears to be rising
among adolescents and young adults. This study suggests
that greater investment in prevention and treatment ac-
tivities may be highly cost-effective.
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Insomnia surpasses other illness in prevalence (40–50%
population), influence on life, economic and time losses.
Pharmacotherapy is the most widespread method of in-
somnia therapy and prophylaxis. There are 28 hypnotic
drugs approved for use throughout Russia. These drugs
are equally effective and distinguished by frequency and
severity of adverse events, effects on quality of life, and
costs. The number of corresponding trials was insufficient
to make the quantitative comparison of these parameters.
We have classified the hypnotic drugs by their ascending
side effects and their descending quality of life into the fol-
lowing sequence: imovan (cyclopyrrolon) and ivadal (imida-
zopyridine), benzodiazepine (22), Donormyl (ethanola-
mine), barbiturates (3). Benzodiazepines are commonly
used drugs which accounted for their low costs, high effec-
tiveness, and prescribing habits. The next generation drugs,
imovan and ivadal, do not have the same sales and required
active promotion, both of which were complicated by the fi-
nancial crash during 1998. As we proposed, benzodiaz-
epines from CIS and Eastern Europe will be the most used
hypnotic drugs during the next 2 years in Russia.
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OBJECTIVE: To quantify the extent to which, from a
managed care perspective, future short-term healthcare
costs are impacted by current alcohol consumption and
smoking.
METHODS: Data for a random sample of 12,185 adult
patients from the Kaiser Permanente Patient Consulta-
tion Study (1992–1995) were used in this analysis. Using
multivariate predictive models, the logarithm of total
healthcare costs over 2 years was regressed on patient-
specific demographic and health status variables as mea-
sured in the baseline year, including measures of comor-
bidity. Alcohol consumption and smoking behaviors
were measured by self-report at baseline. Considering the
skewness of cost distribution, nonparametric tests were
also performed on the models.
RESULTS: Alcohol consumption proved statistically sig-
nificant in reducing total healthcare costs in the basic
model (14.97%, p  0.0001, R2  0.1413). However,
smoking was not found to statistically affect healthcare
costs in the basic regression model. These results were ro-
bust with respect to respecifications of the model that in-
cluded prior costs, levels of smoking and drinking, and the
presence of chronic disease states. Other covariates found
to significantly increase costs were age, female, single or
separated marital status, and being disabled. Compared to
White patients, Asian, Black, and Latino patients incurred
significantly lower healthcare costs in all models.
CONCLUSION: Results from this analysis showed a
negative relationship between alcohol consumption and
short-term healthcare costs while smoking was not found
to affect future costs. However, further studies are neces-
sary to focus on the history of health-related behaviors
rather than current patterns to more closely establish a
link between smoking and drinking and healthcare costs.
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OBJECTIVE: Effective asthma management requires in-
formed active involvement of patients and physicians.
One aspect, physician clinical knowledge, was evaluated
in this study as part of a comprehensive disease manage-
ment strategy to improve the quality of asthma care in a
managed care setting. 
METHODS: A pulmonologist administered a standard-
ized telephone interview to 68 primary care physicians
(72% participation rate). Participants were selected from
a random sample of HMO physicians with at least one
medical or pharmacy claim for asthma in the 6 months
prior to interview. The interview tested basic clinical
knowledge and specific applications of knowledge as out-
lined in the 1997 NIH/NHLBI Guidelines for the Diag-
nosis and Management of Asthma and covered: initial
asthma assessment and diagnosis; pharmacologic ther-
apy; control of factors contributing to asthma severity;
and patient management and education. Each domain
contributed 25 points to the overall score of 100 points. 
RESULTS: The mean overall score among the 68 partici-
pating physicians was 46  9. Overall, domain specific
scores were low. Knowledge regarding environmental
and non-environmental asthma triggers and commonly
recommended control measures was poor. More than
half under-assessed asthma severity based on symptoms
and pulmonary function. Almost 75% incorrectly stated
the indications for the use of long-acting inhaled beta2-
agonists. Almost half did not develop written action
plans with patients for asthma self-management. 
CONCLUSIONS: This survey revealed several key limi-
tations in physicians’ asthma knowledge. These limita-
tions will be addressed in a targeted and tailored physi-
cian educational intervention.
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